---
title: "Takeda's Zasocitinib Shows Rapid, Durable Skin Clearance In Phase 3 Psoriasis Trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280914764.md"
description: "Takeda (TAK) announced promising results from two Phase 3 studies of its oral TYK2 inhibitor, zasocitinib (TAK-279), for treating moderate-to-severe plaque psoriasis. The drug demonstrated rapid and durable skin clearance, with about 70% of patients achieving clear or almost clear skin by week 16. Takeda plans to submit a New Drug Application to the FDA in fiscal year 2026. The study results are not expected to significantly impact the company's fiscal forecast. Takeda's stock closed at $17.91, down 0.83%."
datetime: "2026-03-29T15:14:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280914764.md)
  - [en](https://longbridge.com/en/news/280914764.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280914764.md)
---

# Takeda's Zasocitinib Shows Rapid, Durable Skin Clearance In Phase 3 Psoriasis Trials

Add  as your preferred news source on Google

 Add Now

Takeda (TAK) announced new data from two pivotal Phase 3 studies of zasocitinib (TAK-279), its next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The results highlight that once-daily oral zasocitinib achieved rapid and durable skin clearance, with a safety profile consistent with earlier Phase 2b studies.

In the trials, about 70% of patients treated with zasocitinib reached clear or almost clear skin (sPGA 0/1) by week 16. Additionally, a significantly greater PASI 75 response rate compared to placebo was observed as early as week 4, underscoring the drug's potential for fast-acting efficacy.

Takeda confirmed that it remains on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration and other regulatory authorities beginning in fiscal year 2026.

The company also noted that the Phase 3 study results will not have a significant impact on its consolidated forecast for the fiscal year ending March 31, 2026.

TAK closed regular trading at $17.91 on March 27, 2026. The share price slipped by $0.15, representing a decline of 0.83%.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)

## Related News & Research

- [Takeda’s Phase II/III trial of TAK-881 meets primary endpoint](https://longbridge.com/en/news/285317258.md)
- [Takeda Pharmaceutical (TAK) Expected to Announce Earnings on Wednesday](https://longbridge.com/en/news/285388623.md)
- [Is TAK-881’s Reduced-Volume PID Infusion Data Altering The Investment Case For Takeda (TSE:4502)?](https://longbridge.com/en/news/285527387.md)
- [Takeda Pharmaceutical Announces Positive Data From TAK-881 Trial](https://longbridge.com/en/news/285072325.md)
- [Takeda's psoriasis pill succeeds in late-stage studies](https://longbridge.com/en/news/280886208.md)